Introduction
============

In this second part of our series on systematic reviews in complementary therapies we report our findings on herbal medicines. Herbal medicines (defined as preparations derived from plants and fungi, for example by alcoholic extraction or decoction, used to prevent and treat diseases) are an essential part of traditional medicine in almost any culture \[[@B1]\]. In industrialized countries herbal drugs and supplements are an important market. Some countries like Germany have a long tradition in the use of herbal preparations marketed as drugs and figures for prescriptions and sales are stable or slightly declining \[[@B2]\]. In the US and the UK herbal medicinal products are marketed as \"food supplements\" or \"botanical medicines\". In recent years sales of such products have been increasing strongly in these countries \[[@B3],[@B4]\]. In the Third World herbs are mainly used by traditional healers \[[@B5]\].

Methods
=======

A detailed description of the methods used in this review of reviews is given in the first part of this series \[[@B6]\]. For searches in Medline 50 single plant names and the \'exploded\' term \'medicinal plants\' were combined with the standard search strategy for systematic reviews. As a specific intervention-related inclusion criterion we required that reports reviewed prospective (not necessarily controlled) clinical trials of substances extracted from plants in humans. Reviews dealing with single substances (e.g., artemisin derivatives) derived from plants were excluded on the grounds that such agents are comparable to conventional drugs. Disease-oriented reviews including a variety of interventions were included only if they reviewed at least 4 herbal medicine trials.

Results
=======

From a total of 79 potentially relevant reviews preselected in the literature screening process, 58 (published in 65 papers) met the inclusion criteria \[[@B7]-[@B71]\]. Eleven reports were not truly systematic reviews (not meeting inclusion criterion 2) \[[@B72]-[@B82]\], 5 dealt with isolated substances of plant origin \[[@B83]-[@B87]\] and 4 were excluded for other reasons (one disease- focused review with less than 4 herbal medicine trials \[[@B88]\], one review not on preventative or therapeutic use \[[@B89]\], two reviews not truly herbal medicine \[[@B90],[@B91]\]).

More than half of the reports reviewed gingko, hypericum or garlic preparations. No less than 13 systematic reviews dealed with ginkgo (*Ginkgo biloba*) extracts (see table [1](#T1){ref-type="table"}). Seven of these reviewed trials (total number of trials covered in any of the reviews 15) in patients with intermittent claudication \[[@B7]-[@B13]\]. Most of these reviews concluded that ginkgo extracts were significantly more effective than placebo in increasing measures like walking distance but the clinical relevance of the effects was felt to be moderate by some reviewers. The five reviews dealing with dementia and cerebral insufficiency (total number of trials included about 50) all draw positive conclusions \[[@B13]-[@B17]\]. However, many of the older trials were in patients with minor cognitive impairment and more evidence is needed to decide whether ginkgo extracts have clinically relevant beneficial effects in more severe forms of dementia. Finally, one review found that ginkgo extracts might be effective in the treatment of tinnitus \[[@B18]\] and another found insufficient evidence for efficacy in patients with macular degeneration \[[@B19]\].

###### 

Systematic reviews of clinical trials of ginkgo biloba extracts

                                                                                                Features                                         
  ------------------------------ ---------------- ------------ --------------- ---------------- ---------- ------------------------------------- ---------------------------------------
  **Ginkgo (*Ginkgo biloba*)**                                                                                                                   
  Pittler 2000                   intermittent     ginkgo       placebo         8 RCT            y/y/y/     Increase of pain-free walking         Evidence for a modest benefit of
  \[[@B7]\]                      claudication                                                   y/y        distance over placebo after 12        uncertain clinical relevance
                                                                                                           or 24 weeks 34 m (95%CI 26--          
                                                                                                           43 m)                                 
  Moher 2000                     intermittent     ginkgo^\*^   placebo         5 RCT            y/y/y/     Increase of pain-free walking         Inconsistent results from the few
  \[[@B8]\]                      claudication                                                   n/y        distance over placebo after 24        available small studies do not
                                                                                                           weeks 32 m (95%CI 14--50 m)           allow firm conclusions
  Ernst 96 \[[@B9]\]             intermittent     ginkgo       placebo,        10               p/ p/ n/   Most studies low quality.             Available evidence promising but
                                 claudication     extract      other drugs     RCT/CCT          n/n        Increase of walking distance          further high quality research
                                                  EGb761                                                   compared to placebo 24 to 160         needed
                                                                                                           m\. At least similar                  
                                                                                                           effectiveness compared to             
                                                                                                           other drugs.                          
  Schneider 92                   intermittent     ginkgo       placebo,        7 RCT/CCT        ?/n/n/     mean effect size d = 0.75             Effectiveness over placebo clearly
  \[[@B10]\]                     claudication                  other           (vs. plac.), 2   y/y        (95%CI 0.44--1.07) over               shown
                                                               treatment       RCT/CCT                     placebo                               
                                                                               (other)                                                           
  Letzel 92                      intermittent     ginkgo       ginkgo vs.      5 RCT            ?/p/n/     Pooled increase of walking            Ginkgo extract EGb761 more
  \[[@B11]\]                     claudication     extract      plac.,          ginkgo           y/y        distance: 45% over placebo for        effective than placebo and
                                                  EGb 761      pentoxifyllin   9 RCT                       gingko and 57% for                    similarly effective as pentoxifyllin
                                                               vs. plac.       pentoxifyllin               pentoxifyllin                         
  Kleijnen 91                    intermittent     ginkgo       ginkgo vs.      15               y/y/y/     Many trials low quality. All trials   Ginkgo seems effective for
  \[[@B12]\]                     claudication                  plac.,          RCT/CCT          n/n        with positive results. Evidence       intermittent claudication but further
                                                               pentoxifyllin   (ginkgo), 5                 similar as for pentoxifyllin          high quality studies are needed
                                                               vs. placebo     RCT/CCT                                                           
                                                                               pentoxif.                                                         
  Weiss 91                       cerebral ins.,   ginkgo       placebo         17RCT/CCT        ?/p/p/     10 of 12 interpretable trials on      Effectiveness for both conditions
  \[[@B13]\]                     intermittent     extract                      (cerebral        n/n        cerebral insufficieny and all 4       biometrically shown
                                 claudication     EGb761                       ins.), 8                    interpretable trials on               
                                                                               RCT/CCT                     intermittent claudication with        
                                                                                                           significant positive results          
  Ernst 99 \[[@B14]\]            dementia         ginkgo       placebo         9 RCT            y/y/y/     Results collectively suggest          Encouraging findings warranting
                                                                                                y/n        that ginkgo is more effective for     large scale trials
                                                                                                           dementia than placebo                 
  Oken 98 \[[@B15]\]             Alzheimer        ginkgo       placebo         4 RCT            y/y/n/     Significant effect over placebo       Clinical relevance of the observed
                                 dementia                                                       y/y        for cognitive function (Hedges        effects has to be confirmed in
                                                                                                           g= 0.41, 95%CI 0.22--0.61)            further research
  Hopfenmüller                   cerebral         ginkgo       placebo         10 RCT, 1        n/ n/ n/   Global response (based on             Ginkgo extract superior to placebo
  94 \[[@B16]\]                  insufficiency    extract LI                   CCT              y/y        symptom scores): OR 1.98              
                                                  1370                                                     (95%C11.39--2.57) in favour of        
                                                                                                           Ginkgo                                
  Kleijnen 92                    cerebral         ginkgo       ginkgo vs.      40 RCT/          y/y/y/     Many trials low quality. Virtually    Ginkgo seems effective for
  \[[@B17]\]                     insufficiency                 plac.           CCT              n/n        all trials reported positive          cerebral insufficiency but further
                                                               hydergine       (ginkgo), 4                 results. Evidence similar as for      high quality studies are needed
                                                               vs. plac.       RCT/CCT                     hydergine                             
                                                                               (hydergine)                                                       
  Ernst 99 \[[@B18]\]            tinnitus         ginkgo       placebo,        5 RCT            y/y/y/     3 trials favour ginkgo over           Results suggest that extracts of
                                                               other                            y/n        placebo, 1 no difference, in one      ginkgo biloba are effective in
                                                               treatment (1                                trial ginkgo better than another      treating tinnitus
                                                               trial)                                      treatment                             
  Evans 2000                     macular          ginkgo       placebo         1 RCT            y/y/y/     one small trial reporting             Insufficient evidence to
  \[[@B19]\]                     degeneration                                                   y/-        improvement                           recommend ginkgo for age-related
                                                                                                                                                 macular degeneration

Features: 1 = comprehensive search, 2 = explicit inclusion criteria, 3 = formal quality assessment, 4 = summary of results for each included study, 5 = meta-analysis; y = yes, p = partly, n = no, - = not applicable, ? = unclear review on all pharmacologic treatments for the respective condition RCT = randomized controlled trials, CCT = non-randomized controlled trials, CS = cohort studies, UCS = uncontrolled studies; OR = odds ratio, RR = rate ratio

The effectiveness of St. John\'s wort (*Hypericum perforatum*) extracts in depression was investigated in nine reviews \[[@B20]-[@B30]\] (total number of trials covered 29; see table [2](#T2){ref-type="table"}). Mainly due to slight differences in the inclusion criteria (for example, restriction to trials with a minimum of 6 weeks observation or with a minimum quality score) the respective study collections differed to a considerable amount. However, the conclusions were very similar. Hypericum extracts have been shown to be superior to placebo in mild to moderate depressive disorders. There is growing evidence that hypericum is as effective as other antidepressants for mild to moderate depression and causes fewer side effects but further trials are still needed to establish long-term effectiveness and safety.

###### 

Systematic reviews of clinical trials of hypericum and garlic preparations

                                                                                                           Features                                         
  ---------------------------------------------- -------------- -------------- ----------------- --------- ---------- ------------------------------------- ---------------------------------------
  **St John\'s wort (*Hypericum perforatum*)**                                                                                                              
  Gaster                                         depression     hypericum      placebo and       8 RCT     p/y/p/     4 placebo-controlled trials with      Data suggest that hypericum is
  2000 \[[@B20]\]                                                              antidepressants             y/n        positive results, in 4 trials         superior to placebo, insuffcient
                                                                                                                      standard antidepr. tended to be       evidence re equivalence with
                                                                                                                      slightly better                       antidepressants
  Williams                                       depression     hypericum      placebo and       14 RCT    y/y/n/     Treatment response: RR 1.9            Data suggest that hypericum is
  2000 &                                                        (and other     antidepressants             y/y        (95%C11.2--2.8) vs. placebo and       superior to placebo, insuffcient
  Mulrow 98                                                     drugs)                                                1.2 (1.0--1.4) vs. antidepressants    evidence re equivalence with
  \[[@B21],[@B22]\]                                                                                                                                         antidepressants
  Kim 99 \[[@B23]\]                              depression     hypericum      placebo and       6 RCT     p/y/y/     Treatment response: RR 1.48           Hypericum more effective than
                                                                               antidepressants             y/y        (95%C11.03--1.92) vs. placebo         placebo and similarly effective as
                                                                                                                      and 0.98 (0.67--1.28) vs.             low dose antidepressants; quality
                                                                                                                      antidepressants                       problems
  Stevinson                                      depression     hypericum      placebo and       6 RCT     y/y/y/     Only trials published after Linde     Data confirm findings of earlier
  99 \[[@B24]\]                                                                antidepressants             y/n        96; trials show effects better        trials, but still insuff. evidence to
                                                                                                                      than placebo/similar to               assess equivalence with
                                                                                                                      antidepressants                       antidepressants
  Linde 98 &                                     depression     hypericum      placebo and       27 RCT    y/y/y/     Treatment response: RR 2.47           Hypericum more effective than
  96 \[[@B25],[@B26]\]                                                         antidepressants             y/y        (95%C11.69--3.61) vs. placebo         placebo. Inadequate evidence to
                                                                                                                      and 1.01 (0.87--1.16) vs.             assess equivalence with
                                                                                                                      antidepressants                       antidepressants
  Volz 97                                        depression     hypericum      placebo and       15        p/p/n/     Most placebo-controlled trials        A therapy with hypericum of mild
  \[[@B27]\]                                                                   antidepressants   RCT/CCT   n/n        positive; similarly effective as      and moderate depression can be
                                                                                                                      (not adequately dosed)                attempted. Further studies needed
                                                                                                                      antidepressants                       
  Ernst 95                                       depression     hypericum      placebo and       11 RCT    y/y/y/     Most of 8 placebo-controlled          Hypericum is superior to placebo
  \[[@B28]\]                                                                   antidepressants             y/n        trials positive. 3 trials against     and seems equally effective as
                                                                                                                      standard medication with similar      standard medication
                                                                                                                      effects                               
  Volz 2000                                      mild to        hypericum      fluoxetine        17+9      n/y/n/     No direct comparison of               Response rates are similar;
  \[[@B29]\]                                     mod.                                            CCT       y/n        hypericum and fluoxetine              findings difficult to interpret
                                                 depression                                                           available. Mean depression            because of the indirect comparison
                                                                                                                      score (HAMD) reduction in             
                                                                                                                      hypericum trials 53%, in              
                                                                                                                      fluoxetine trials 55%                 
  Friede 98                                      anxiety in     hypericum      placebo,          8 RCT     ?/y/y/     Trials collectively show reduction    Hypericum is effective for
  \[[@B30]\]                                     depressed                     amitriptyline               y/n        of anxiety symptoms over              depressed patients with anxiety
                                                 p\.                                                                  placebo. Only 1 trial vs              
                                                                                                                      amitriptyline                         
  **Garlic (*Allium sativum*)**                                                                                                                             
  Lawrence                                       cardiovasc.    garlic         mainly placebo;   45 RCT    y/y/y/     37 trials consistently show small     Insufficient data to draw conclusion
  2000 \[[@B31]\]                                risk factors                  no & other                  y/y        short-term effects over placebo       regarding clinical cardiovascular
                                                                               treatment                              for cholesterol reduction. No         outcomes. Garlic preparations may
                                                                                                                      consistent effects on blood           have small, positive, short-term
                                                                                                                      pressure, promising effects re        effects on lipids
                                                                                                                      platelet aggregation and              
                                                                                                                      fibrionolytic activity                
  Stevinson                                      hyperchol-     garlic         placebo           13 RCT    y/y/y/     Pooled total cholesterol              Available data suggest that garlic is
  2000 \[[@B32]\]                                esterolemia                                               y/y        reduction over placebo 0.41           superior to placebo. The size of the
                                                                                                                      (95% Cl -0.66 to -0.15) mmol/l;       effect is modest. The use of garlic
                                                                                                                      when analysis restricted to high      for hyperchol. is therefore of
                                                                                                                      quality trials 0.11 (-0.30 to 0.08)   questionable value
  Silagy 94 &                                    cholesterol    garlic         placebo           16 RCT    y/p/y/     Pooled cholesterol reduction          Meta-analysis suggests positive
  Neil 96                                        lowering                                                  y/y        over placebo 0.65 (95% Cl 0.53--      effects but reviewers are sceptic
  \[[@B33],[@B34]\]                                                                                                   0.76) mmol/l                          (low quality; own replication
                                                                                                                                                            negative)
  Warshafsky                                     cholesterol    garlic         placebo           5 RCT     p/y/y/     Pooled cholesterol reduction          Available evidence supports the
  93 \[[@B35]\]                                  lowering                                                  y/y        over placebo 0.59 (95%Cl 0.44--       use of garlic as one modality to
                                                                                                                      0.74) mmol/l                          decrease cholesterol levels
  Silagy 94                                      lowering       dried garlic   placebo, other    8 RCT     y/p/y/     Pooled reduction over placebo:        Garlic maybe of some clinical use
  \[[@B36]\]                                     blood          (Kwai)         treatment                   y/y        SBP 7.7 (95% Cl 4.3--11.0), DBP       in subjects with mild hypertension.
                                                 press.                                                               5.0 (2.9--7.1) mm Hg                  Further research needed
  Kleijnen 91                                    cardiovasc.    garlic         placebo           18        p/p/y/     Most studies with shortcomings.       No clear conclusion drawn
  \[[@B37]\]                                     risk factors   supplements                      RCT/CCT   y/n        The majority of trials with pos.      
                                                                                                                      results but inconsistent effect       
                                                                                                                      sizes                                 
  Kleijnen 89                                    cardiovasc.    garlic &       unclear           10 RCT,   y/p/n/     All trials with severe                Inadequate evidence to justify
  \[[@B38]\]                                     risk factors   onions                           8 CCT     y/n        shortcomings. Fresh garlic with       supplementation, further research
                                                                                                                      beneficial effcts, onions and         needed
                                                                                                                      commercially available                
                                                                                                                      supplements yielded                   
                                                                                                                      contradictory results                 
  Jepson 97                                      lower limb     garlic         placebo           1 RCT     y/y/y/     Walking distance not                  Insufficient evidence
  \[[@B39]\]                                     atheroscler.                                              y/-        significantly different between       
                                                                                                                      groups                                

legend see table [1](#T1){ref-type="table"}

Eight reviews have been performed on garlic (*Allium sativum*) for cardiovascular risk factors \[[@B31]-[@B38]\] (total number of trials covered about 50) and lower limb atherosclerosis \[[@B39]\] (see table [2](#T2){ref-type="table"}). A modest short-term effect over placebo on lipid-lowering seems to be established but the clinical relevance of these effects is uncertain. Data from randomised trials on cardiovascular mortality are not available. Effects on blood pressure seem to be at best minor. The available results on fibrinolytic activity and platelet aggregation are promising but insufficient to draw clear conclusions. A specific problem in research on garlic is the great variety of garlic preparations used: the exact content of bioactive ingredients in these is often unclear.

Three reviews (covering a total of about 30 trials) have been performed on preparations containing extracts of Echinacea (*Echinacea purpurea, pallida or angustifolia*), two of which by the same study group \[[@B40]-[@B43]\]. The results suggest that Echinacea preparations may have some beneficial effects mainly in the early treatment of common colds. Similar to garlic a major problem is the high variaton of bioactive compounds between different Echinacea preparations. Cranberries (*Vaccinium macrocarpon*) for urinary tract infections \[[@B44],[@B45]\], mistletoe (*Viscum album*) for cancer \[[@B46]-[@B48]\], peppermint (*Mentha piperita*) oil for irritable bowel syndromes \[[@B49],[@B50]\] and saw palmetto (*Serenoa repens*) for benign prostate hyperplasia \[[@B51]-[@B53]\] have each been subject to two reviews. For saw palmetto there is good evidence for efficacy over placebo while for the other three the data are inconclusive (see table [3](#T3){ref-type="table"}).

###### 

Systematic reviews of clinical trials of herbal medicines (at least 2 reviews per herb)

                                                                                                                              Features                                            
  ---------------------------------------------------------------- ------------- ---------------- --------------- ----------- ---------- ---------------------------------------- -----------------------------------------
  **Echinacea (*Echinacea purpurea, angustifolia and pallida*)**                                                                                                                  
  Barrett                                                          upper resp.   echinacea        placebo         13RCT       y/p/y/     Overall quality modest. All 4            Echinacea may be beneficial for
  99 \[[@B40]\]                                                    infections    (incl.                                       y/n        prevention studies show only             early treatment of acute upper
                                                                                 combinations)                                           minor trends, 8 of 9 treatment           respiratory infections; little evidence
                                                                                                                                         studies with generally positive          to support the prolonged use for
                                                                                                                                         results                                  prevention
  Melchart                                                         common        echinacea        placebo, no     16 RCT      y/y/y/     Minor effects in prevention and          Echinacea extract can be efficacious
  99 \[[@B41]\]                                                    cold          (incl.           treatment                   y/p        treatment, promising effects in          for the common cold, but evidence
                                                                                 combinations)                                           early treatment. Heterogen.              insufficient for recommendations
                                                                                                                                         preparations                             
  Melchart                                                         immuno-       echinacea        placebo, no     18 RCT, 8   y/y/y/     Most studies low quality. Most           Echinacea extracts can be
  94                                                               stimulation   (incl.           treatment       CCT         y/n        studies show immunostimulating           efficacious immunostimulators, but
  \[[@B42],[@B43]\]                                                              combinations)                                           effects                                  evidence insufficient for
                                                                                                                                                                                  recommendations
  **Cranberries (*Vaccinium macrocarpon*)**                                                                                                                                       
  Jepson                                                           urinary       cranberries      placebo         4 RCT       y/y/y/     In 3 of 4 trials cranberries effective   Insufficient evidence, further research
  98 \[[@B44]\]                                                    tract inf.                                                 y/n        for at least one of the outcomes of      needed
                                                                   (prevent)                                                             interest                                 
  Jepson                                                           urinary       cranberries                      O RCT       y/y/-/     No trials meeting the inclusion          No evidence available
  98 \[[@B45]\]                                                    tract inf.                                                 -/-        criteria                                 
                                                                   (treatm.)                                                                                                      
  **Mistletoe (*Viscum album*)**                                                                                                                                                  
  Kleijnen                                                         cancer        mistletoe        placebo, no     11          y/y/y/     Most studies low quality. Most           Insufficient evidence to recommend
  94 \[[@B46]\]                                                                                   treatment       RCT/CCT     n/n        studies show longer survival with        mistletoe outside of clinical trials
                                                                                                                                         mistletoe but not the best trial         
  Kiene 89                                                         cancer        mistletoe        no treatment,   2 RCT, 33   y/n/n/     Most studies low quality. 9 of 12        Available evidence supports positive
  \[[@B47],[@B48]\]                                                                               none            CCT, 11     y/n        interpretable studies suggest            effects of mistletoe
                                                                                                                  other                  positive effects on survival             
                                                                                                                  studies                                                         
  **Peppermint (*Mentha piperita*)**                                                                                                                                              
  Jailwala                                                         irritable     1\. peppermint   placebo         1\. 3 RCT   p/y/y/     Chinese herbal therapy trial rated       In both cases efficacy not clearly
  2000^\*^                                                         bowel         oil                              2\. 1 RCT   n/n        as positive, one of three                established
  \[[@B49]\]                                                       syndr.        2\. Chinese                                             peppermint oil trials rated as           
                                                                                 herbal                                                  positive                                 
                                                                                 therapy                                                                                          
  Pittler 98                                                       irritable     peppermint       placebo,        8 RCT       y/y/y/     Global improvement rates                 The role of peppermint oil for IBS
  \[[@B50]\]                                                       bowel         oil              other                       y/y        significantly higher compared to         has not been established beyond
                                                                   syndr.                         treatment                              placebo. Quality of trials doubtful      reasonable doubt
  **Saw palmetto (*Serenoa repens*)**                                                                                                                                             
  Boyle                                                            ben.          Permixon^®^      placebo,        11 RCTs,    ?/n/n/     peak urine flow 2.20 (95% Cl 1.20--      Despite some limitations strong
  2000 \[[@B51]\]                                                  prostate      (saw             other           2 UCS       y/y        3.20) ml/s increase over placebo;        evidence that the extract tested has
                                                                   hyperplasia   palmetto)        treatment                              significant decrease nocturia            beneficial effects
  Wilt 2000                                                        ben.          saw palmetto     placebo,        14 RCT      y/y/y/     Saw palmetto superior to placebo         Evidence suggests that saw
  &98                                                              prostate                       other           (plac),     y/y        for nocturia, self rating, peak urine    palmetto improves urological
  \[[@B52],[@B53]\]                                                hyperplasia                    treatment       5 RCT                  flow; similar effects as finasteride     symptoms and flow measures.
                                                                                                                  (other)                                                         Further studies needed

legend see table [1](#T1){ref-type="table"}

Single systematic reviews have been published on aloe (*Aloe vera*) \[[@B54]\], artichoke (*Cynara scolymus*) leave extract \[[@B55]\], evening primrose (*Oenothera biennis*) oil \[[@B56]\], feverfew (*Tanacetum parthenium*) \[[@B57]\], ginger (*Zingiber officinialis*) \[[@B58]\], ginseng (*Panax ginseng*) \[[@B59]\], horse chestnut (*Aesculus hippocastanum*) seeds \[[@B60]\], kava (*Piper methysticum*) \[[@B61]\], milk thistle (*Silybum marianum*) \[[@B62]\], a fixed combination of three herbal extracts \[[@B63]\], rye-grass pollen (*Secale cereale*) extract \[[@B64],[@B65]\], tea tree (*Melaleuca alternafolia*) oil \[[@B66]\], and valerian (*Valehana officinalis*) root \[[@B67]\] (see table [4](#T4){ref-type="table"}). The only review which focused on a herbal intervention which is not marketed as a drug or food supplement was on cabbage leaves for breast engorgement and included a single small-scale trial \[[@B68]\]. Chinese herbal therapy for atopic eczema \[[@B69]\] and a variety of herbs for lowering blood glucose \[[@B70]\] and for analgesic and anti-inflammatory purposes \[[@B71]\] have also been reviewed. For some of these herbal preparations the evidence is promising but further studies are considered necessary to establish efficacy in almost every case.

###### 

Systematic reviews of clinical trials of herbal medicines

                                                                                  Features                                       
  ------------------- --------------- --------------- ---------------- ---------- ---------- ----------------------------------- --------------------------------------
  Vogler 99           various         aloe            placebo, other   6 RCT,4    y/y/y/     Positive results for genital        Promising results, but overall
  \[[@B54]\]                                          & no treatment   CCT        y/n        herpes, psoriasis, hyper-           evidence insufficient
                                                                                             lipidemia, diabetes;                
                                                                                             contradictory for wound healing     
  Pittler 98          cholesterol     artichoke       placebo          1 RCT      y/y/y/     Effects over placebo only in the    More trials needed
  \[[@B55]\]          lowering        leave                                       n/n        subgroup of participants with       
                                      extract                                                serum cholesterol \> 210 mg/dl      
  Morse 89            atopic          evening         placebo          9          ?/n/n/     Epogam significantly better         No conclusion drawn
  \[[@B56]\]          eczema          primrose oil                     RCT/CCT    y/y        than placebo for most               
                                      (Epogam)                                               outcomes                            
  Vogler 98           migraine        feverfew        placebo          5 RCT      y/y/y/     Majority of trials favor feverfew   Effectiveness has not been
  \[[@B57]\]                                                                      y/n        over placebo                        established beyond reasonable
                                                                                                                                 doubt
  Ernst 2000          nausea and      ginger root     placebo,         6 RCT      y/y/y/     2 of 3 trials on postoperative      Evidence promising but insufficient
  \[[@B58]\]          vomiting                        metoclopramide              y/p        nausea positive (best               to draw firm conclusions
                                                                                             negative), trials on                
                                                                                             seasickness, morning sickness       
                                                                                             and chemotherapy-induced            
                                                                                             nausea positive                     
  Vogler 99           various         ginseng root    placebo, other   16 RCT     y/p/y/     Contradictory results re.           The efficacy of ginseng root extract
  \[[@B59]\]                          extract         treatment (1                y/n        physical performance (7 trials),    is not established beyond
                                                      trial)                                 psychological function (5),         reasonable doubt for any of these
                                                                                             immunomodulation (2),               indications
                                                                                             positive results in diabetes and    
                                                                                             herpes simplex (1 trial             
                                                                                             respectively)                       
  Pittler 98          venous          horse           placebo, other   13 RCT     y/y/y/     Significant effects over placebo    horse chestnut seeds seem to be
  \[[@B60]\]          insufficieny    chestnut        treatment                   y/n        and similar effects compared to     effective; further tials needed
                                      seeds                                                  other treatments                    (confirmation, long-term results,
                                                                                                                                 combination)
  Pittler 2000        anxiety         kava            placebo          7 RCT      y/y/y/     All trials suggest superiority      Available data suggest that kava is
  \[[@B61]\]                                                                      p/p        over placebo; 3 trials with data    a treatment option for anxiety.
                                                                                             for meta-analysis show sign.        Further studies needed
                                                                                             superiority                         
  Lawrence            liver           milk thistle    placebo, other   33 RCT,    y/y/y/     Variety of conditions studied,      Efficacy is not established.
  2000 \[[@B62]\]     diseases                        & no treatment   1 CCT      y/y        studies often poor quality.         Possible benefit shown most
                                                                                             Mixed and inconsistent findings     frequently for aminotransferases.
  Ernst 99            musculoskel.    Phytodolor^®^   placebo, other   10 RCT     y/p/y/     Placebo-controlled trials show      The data suggest that the
  \[[@B63]\]          pain            populus,        treatments                  y/n        superiority over placebo and        combination is effective in the
                                      fraxinus,                                              similar effects as NSAIDs           symptomatic treatment of
                                      solidago                                                                                   muskuloskeletal pain
  MacDonald           ben. prostata   rye grass       placebo, other   4 RCT      y/y/y/     Signif. improvement over            Available evidence suggests that
  2000 &              hyperplasia     pollen          therapy                     y/y        placebo in subjective, but not      Cernilton^®^ is well tolerated and
  Wilt 2000                           extract                                                objective symptoms; no              modestly improves subjective
  \[[@B64],[@B65]\]                                                                          differences compared to             symptoms. Further studies needed
                                                                                             tadenan and paraprost               
  Ernst 2000          dermatologic    tea trea oil    placebo, other   4 RCT      y/y/y/     2 trials vs. placebo positive, 3    Data promising but insufficient
  \[[@B66]\]          conditions                      treatment                   y/n        trials vs. other treatments         
                                                                                             similar effects                     
  Stevinson           insomnia        valerian root   placebo          9 RCT      y/y/y/     Highly heterogeneous studies        Available evidence is promising but
  2000 \[[@B67]\]                                                                 y/n        with sometimes contradictory        not fully conclusive. Further,
                                                                                             and inconsistent findings           rigorous trials needed
  Renfrew             breast          cabbage         usual care       1 RCT      y/y/n/     fewer women stopping breast         Further research desirable
  84 \[[@B68]\]       engorgement     leaves                                      y/n        feeding among those receiving       
                                                                                             cabbage leaves                      
  Armstrong           atopic          Chinese         placebo          2 RCT      y/y/n/     2 positive studies by the same      Evidence encouraging but
  99 \[[@B69]\]       eczema          herbal                                      *y/n*                                          insufficient given the potential of
                                      therapy                                                treat analysis                      relevant side effects
  Ernst 97            hypoglyc.       all plants      no treatment,    7 RCT, 4   y/p/n/     Most studies low quality. Most      Use of hypoglcemic plant remedies
  \[[@B70]\]          activity                        placebo, none    CCT, 10    y/n        papers report positive effects      not supported by rigorous
                                                                       UCS                   on a variety of plants              research. Further studies required
  Ernst 2000          analgetic or    various         placebo          18 RCT     y/y/y/     Trials on evening primrose oil,     The results suggest that several
  \[[@B71]\]          inflamm.                                                    y/n        blackcurrant seed oil, borage       herbal remedies have potential in
                      treatment                                                              oil, harpagophytum, willow          alleviating the pain of rheumatic
                                                                                             bark, feverfew, and 3               diseases. More research urgently
                                                                                             combinations; almost all trials     needed
                                                                                             positive                            

legend see table [1](#T1){ref-type="table"}

Discussion
==========

Our overview shows that a considerable number of systematic reviews on herbal medicines is available. In the majority of cases the reviewers considered the available evidence as promising but only very rarely as convincing and sufficient as a firm basis for clinical decisions. The methodological quality of the primary studies has been criticized by many reviewers.

Our summary of the existing studies must be interpreted with caution. What we performed is a systematic review of systematic reviews which inherently bears a large risk of oversimplification. Readers who want to reliably assess the evidence for a given herb for a defined condition should read the respective reviews. Our collection -- which to the best of our knowledge is complete up to summer 2000 -- is aimed at facilitating the access and giving an idea of the amount of the available evidence. Based on the increase of herbal medicine reviews in recent years we expect that at least ten new publications will become available in the year 2001.

Most of the currently available systematic reviews address herbal preparations which are marketed and widely used in industrialized countries. However, the widespread traditional use of herbs in the Third World is rarely ever investigated and has not been subjected to systematic reviews. The many herbs used in folk medicine or other traditional uses of herbs (for example, hypericum is used for a variety of ailments other than depression including enuresis, diarrhoea, gastritis, bronchitis, asthma, sleeping disorders etc.) seem to be rarely investigated. Furthermore, practitioners of herbal medicine often combine different herbs and use unconventional diagnostic approaches to adapt prescriptions to single patients. It seems likely that these traditional forms of herbal medicine will remain underresearched relative to single herbal preparations due to the lack of financial incentive for sponsors and due to methodological problems.

Herbal medicines products are not, in general, subject to patent protection. This reduces the motivation for drug companies to invest in trials. Many of the existing herbal medicine manufacturers are comparably small companies, often with limited research resources and expertise. Maybe partly for these reasons, the quality of many older herbal medicine trials is low. Furthermore, negative trials which could threaten the company\'s survival might not become published.

A fundamental problem in all clinical research of herbal medicines is whether different products, extracts, or even different lots of the same extract are comparable and equivalent. This is a major issue in the expert research community and a major obstacle to a reliable assessment for the non-expert. For example, Echinacea products can contain other plant extracts, use different plant species (*E. purpurea, pallida or angustifolia*), different parts (herb, root, both), and might have been produced in quite different manners (hydro- or lipophilic extraction). Pooling studies that use different herbal products in a quantitative meta- analysis can be misleading. Health care professionals and patients considering to prescribe or take a particluar herbal product should check carefully whether the respective product or extract has been tested in the trials included in a review. On the health food store shelf the high quality, standardized products used in the trials might not be available. Only a herbal medicine expert can judge with some certainty whether the results can be extrapolated to the product of interest.

On the level of health care policies the available systematic reviews more often provide insight into the deficiencies of the evidence than guidance for decision making. Trials on hard endpoints are very rarely available and observation periods have generally been short. The clinical relevance of the observed effects is not always clear.

Herbal medicines are generally considered as comparably safe. While this is probably correct case reports show that severe side effects and relevant interactions with other drugs *can* occur. For example, hypericum extracts cause considerably fewer side effects than tricyclic antidepressants \[[@B92]\] but can decrease the concentration of a variety of other drugs by enzyme induction \[[@B93]\]. Several reviews summarizing side effects and interactions have been published \[[@B94]-[@B98]\].

In conclusion, the systematic reviews collected for this analysis are a good tool to get an overview of the available evidence from clinical trials in the area of herbal medicine. However, applying the findings to patients care is problematic for those who are not experts in herbal medicine. In this case it might be better to directly search the literature for clinical trials of the respective product.
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